Curiously, VPRBP inhibition potentially produces two opposing effects on tumor development by suppressing tumor cell growth by activation of p53 (Fig. 4a–c) while also allowing tumor cells to evade immunosurveillance through increased PD-L1 levels (Figs. 1–3). Here, TP53 is linked to neoplasm.